The Top Healthcare Stocks to Buy With $100

Growth or dividend investors can buy two top healthcare stocks with $100 for capital gains or passive income.

The healthcare sector was hardly talked about in 2023 because it lagged the broader market for most of the year. However, for 2024, two companies are excellent choices for growth or dividend investing.   

WELL Health Technologies’s (TSX: WELL) robust growth potential is undeniable with its growing network and adoption of artificial intelligence. Medical Facilities (TSX: DR) is enticing for its unique business model, strong financial performance, and competitive dividend yield. You can start small or with $100 to buy these healthcare stocks.

A game changer in healthcare

WELL Health is well-positioned for a break out, if not explosive growth, soon. The current share price is $3.73, and market analysts’ 12-month average price target is $7.69 (+106%). This $895.66 million digital healthcare company continues to expand its network through acquisitions and investments while focusing on artificial intelligence (AI).

In October 2023, WELL completed a strategic transaction with HEALWELL AI. “Investing in and developing AI-enabled tools and technologies for care providers is of core interest to WELL,” said Hamed Shahbazi, WELL’s founder and chief executive officer (CEO). Shabazi added that WELL commits to revolutionizing and positively impacting Canadian healthcare with secure and responsibly configured AI technologies.

HEALWELL recently acquired Intrahealth, a SaaS-based enterprise class multi-national EHR (electronic health record). It will deeply integrate its AI tools with Intrahealth to create a next-generation AI-Powered EHR. Moreover, through Intrahealth’s platform, HEALWELL can expand its client base from single doctor’s offices to multi-thousand-user health institutions.

Unique business model

Medical Facilities has four specialty surgical hospitals and one ambulatory surgical centre (ownership stakes in some others) in the United States. Management wants to be differentiated by its personalized approach to patient care.

This $238.7 million Canadian company partners with physicians, some of whom are owners themselves, and non-owner physicians can practice at the facilities. The volume in inpatient and outpatient bases where diagnostic, imaging, pain management, and non-emergency surgical procedures are performed is very high.

The case mix in each facility varies depending on physician specialty, medical staff, equipment and infrastructure at each facility. Orthopedic and neurosurgical procedures represent large case volumes at the hospitals. From an investment standpoint, the high-quality facilities and ever-growing outpatient services market are compelling reasons to invest in DR.

In the first three quarters of 2023, total revenue and facility service revenue increased 5.2% and 6% year over year to US$307.3 million and US$323.3 million. Notably, net income jumped 51.5% to US$23.7 million from a year ago. In the third quarter (Q3) of 2023, net income reached US$4.8 million compared to the US$5.5 million net loss in Q3 2022.

Its president and CEO, Jason Redman, said it was another quarter of solid performance, as evidenced by higher revenue, corporate savings, and profitability. “The divestiture of non-core assets not only strengthens our financial position but also allows MFC to better concentrate on supporting our physician partners in providing the best patient experience and hospital care,” Redman added.

Besides reducing corporate debt further, Redman said Medical Facilities will focus on maintaining a strong and sustainable financial structure and creating long-term shareholder value. At $6.54 per share (+6.94% year to date), the dividend yield is 3.38%.

Top sector picks

The healthcare stocks in focus are about to bring life to the underperforming sector. WELL Health could deliver outsized gains, while Medical Facilities is a lucrative option for income investors.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

person with spyglass looks at ocean horizon
Dividend Stocks

Dividend Investors: Don’t Overlook Peyto! Its Yield Is a Thing of Beauty

Peyto Exploration & Development (TSX:PEY) is an underrated energy stock with a colossal yield and a dirt-cheap multiple.

Read more »

Piggy bank wrapped in Christmas string lights
Dividend Stocks

The $7,000 TFSA Move Most Canadians Leave Until December

An earlier TFSA contribution can simplify your plan, even when the immediate tax saving is smaller than you expect.

Read more »

diversification is an important part of building a stable portfolio
Dividend Stocks

Diversification 101: How Beginners Can Protect Against Market Shocks

Stocks like TD Bank and Fortis provide an anchor to a well-diversified portfolio for resilient long-term performance.

Read more »

man makes the timeout gesture with his hands
Dividend Stocks

Why Dividend Cuts Happen and How to Spot the Warning Signs

Learn why dividend cuts happen and how to spot warning signs, using BCE and TELUS to examine cash flow, debt,…

Read more »

woman stares at chocolate layer cake
Dividend Stocks

Just Turned 50 With Little Saved? Here’s Where to Start

This investing strategy can reduce risk while still delivering decent yield.

Read more »

Trans Alaska Pipeline with Autumn Colors
Dividend Stocks

1 Top Canadian Dividend Stock Down 17% to Consider Now for Lifelong Income

This company has increased the dividend annually for more than three decades.

Read more »

Senior uses a laptop computer
Dividend Stocks

A 4.9% Dividend Stock I Plan to Hold Long Term: What $5,000 Would Collect

This is a solid utility stock to consider on dips for a long-term portfolio with a focus on growing income.

Read more »

shopper carries paper bags with purchases
Dividend Stocks

Your GIC Pays 3% to 4%: This TSX Stock Pays You Every Month Instead

SmartCentres pays more income than an illustrative GIC, but a modest unit-price decline could erase the first-year advantage.

Read more »